Podium Presentations
Monday, 6 November 2017
11:15 - 12:15
BREAKOUT SESSION

11:15 - 12:15
Room: Lomond Auditorium (Loch Suite)
P1: COST-EFFECTIVENESS STUDIES
Moderator: Manuela A. Joore
Professor of Health Technology Assessment & Decision Making, Department of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Maastricht, The Netherlands

CE1

11:15 - 11:30

COST-EFFECTIVENESS OF DABIGATRAN WITH REAL WORLD EFFECTIVENESS EVIDENCE

de Pouvourville G1, Guilmet C2, Cohen AA3, Le Dissez C4, Luciani L4, Le Lay K4
1ESSEC Business School, Cergy-Pontoise, France, 2MAPI Group, Nanterre, France, 3Hôpital saint Antoine, Paris, France, 4Boehringer Ingelheim France, Paris, France

CE2

11:30 - 11:45

COST-EFFECTIVENESS ANALYSIS OF MIDOSTAURIN (MIDO) WITH STANDARD CHEMOTHERAPY (SOC) FOR ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)

Tremblay G1, Dolph M1, Patel S2, Brandt P3, Forsythe A1
1Purple Squirrel Economics, New York, NY, USA, 2Novartis Pharmaceuticals UK Limited, Camberley, Surrey, UK, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

CE3

11:45 - 12:00

FIRST-LINE PEMBROLIZUMAB IN PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS FROM A UK HEALTHCARE PERSPECTIVE

Hu X, Goldman DP
University of Southern California, Los Angeles, CA, USA

CE4

12:00 - 12:15

THE EFFECTIVENESS AND COST-EFFECTIVENESS OF TOBACCO CONTROL MASS MEDIA CAMPAIGNS IN SCOTLAND

Haghpanahan H1, Boyd KA1, Mackay DF1, Mcintosh E1, Pell J1, Haw S2
1University of Glasgow, Glasgow, UK, 2University of Stirling, Stirling, UK

11:15 - 12:15
Room: Forth (Armadillo)
P2: CANCER STUDIES
Moderator: Margreet G. Franken, PhD
Senior Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

CN1

11:15 - 11:30

USE OF NEW THERAPIES AND HOSPITAL ADMISSION NEAR THE END OF LIFE IN CASTRATION RESISTANT PROSTATE CANCER (CRPC) IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (CAPRI) IN THE NETHERLANDS

Kuppen M1, Westgeest H1, Van den Eertwegh A2, Gerritsen W3, Uyl - de Groot C1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands, 3Radboud University Medical Center, Nijmegen, The Netherlands

CN2

11:30 - 11:45

THE GRETA STUDY: GENERATING REAL-WORLD EVIDENCE ABOUT BEVACIZUMAB TREATMENT OF METASTATIC COLORECTAL CANCER BY LINKING CANCER REGISTRIES AND HEALTHCARE DATABASES IN ITALY

Franchi M1, Caputo A2, Barni S3, De Ceglie MC4, Mazzucco W5, Ricci P6, Tagliabue G7, Tumino R8, Corrao G9
1University of Milano-Bicocca, Milano, Italy, 2Roche S.p.A., Monza, Italy, 3ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, Italy, 4Roche S.p.A, Monza, Italy, 5University of Palermo, Palermo, Italy, 6Health Protection Agency Mantua&Cremona, NHS Italy, Mantova, Italy, 7Fondazione IRCCS National Cancer Institute, Milano, Italy, 8Provincial Health Authority, ASP Ragusa, Ragusa, Italy, 9Università di Milano-Bicocca, Milan, Italy

CN3

11:45 - 12:00

ASSESSING THE CONSISTENCY IN REPORTING OF ADVERSE EVENTS ACROSS DATA SOURCES FOR MULTIPLE MYELOMA TREATMENT

Kish J, Feinberg B
Cardinal Health Specialty Solutions, Dublin, OH, USA

CN4

12:00 - 12:15

UTILIZATION AND TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PREDICTIVE MOLECULAR BIOMARKER (BMX) TESTS

Kothari S1, Arunachalam A2, Tsao M3, Lee DH4, Kambartel K5, Isobe H6, Huang M7, Escosteguy Barrios CH8, Khattak A9, de Marinis F10, Cao X11, Burke T12, Lopez MA13, De Castro J14
1Merck & Co, Kenilworth, NJ, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, 4Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), 5Bethanien Hospital, Moers, Germany, 6KKR Sapporo Medical Center, Sapporo, Japan, 7Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, 8PUCRS School of Medicine, Porto Alegre, Brazil, 9FIona Stanley Hospital, Murdoch, Australia, 10European Institute of Oncology, Milan, Italy, 11Merck & Co, Inc, Kenilworth, NJ, USA, 12Merck & Co., Inc., Lebanon, NJ, USA, 13MSD, Madrid, Spain, 14Hospital Universitario La Paz, MADRID, Spain
14:15 - 15:15
BREAKOUT SESSION

14:15 - 15:15
Room: Lomond Auditorium (Loch Suite)
P3: STUDIES ON HEALTH TECHNOLOGY ASSESSMENT AGENCIES
Moderator: Allan Wailoo, PhD
Professor of Health Economics,, University of Sheffield and Director, NICE Decision Support Unit, Sheffield, UK

HT1

14:15 - 14:30

PLAYING IN THE SAME POND - THE IMPACT OF BREXIT ON CLINICAL TRIALS AND ACCESS

Wang GD, Macaulay R
PAREXEL International, London, UK

HT2

14:30 - 14:45

HEALTH TECHNOLOGY ASSESSMENT DECISIONS IN IMMUNO-ONCOLOGY THERAPIES: RESULTS, RATIONALES, AND TRENDS

Campbell CM, Nguyen VB, Clark RS, Meyer KL
Xcenda, LLC, Palm Harbor, FL, USA

HT3

14:45 - 15:00

ANALYSIS OF FACTORS INFLUENCING THE LEVEL OF ACTUAL BENEFIT IN HEALTH TECHNOLOGY ASSESSMENT

Bouschon M1, Li J2, Barthelemy C3
1Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, 2Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France, 3Assisance Publique des Hôpitaux de Paris (AP-HP), Paris, France

HT4

15:00 - 15:15

USING REAL-WORLD DATA (RWD) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICE: A COMPARATIVE STUDY OF 5 HTA AGENCIES

Makady A1, van Veelen A2, Jonsson P3, Moseley O4, D'Andon A5, de Boer A2, Hillege JL6, Klungel O2, Goettsch W7
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Utrecht University, Utrecht, The Netherlands, 3National Institute for Health and Care Excellence (NICE), Manchester, UK, 4Scottish Medicines Consortium, 50 West Nile Street, UK, 5French National Authority for Health, Saint Denis La Plaine, France, 6University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 7Utrecht University, UTRECHT, The Netherlands

14:15 - 15:15
Room: Hall 1
P4: RESEARCH ON METHODS
Moderator: Andrea Manca
Professor, Centre for Health Economics, University of York, Heslington, York, UK

RM1

14:15 - 14:30

NETWORK META-ANALYSIS OF HAZARD RATIOS VS. FRACTIONAL POLYNOMIALS APPROACH IN A COST-EFFECTIVENESS ANALYSIS CONSIDERING ADVANCED GASTRIC CANCER

Cranmer HL, Harvey RC
Tolley Health Economics Ltd., Buxton, UK

RM2

14:30 - 14:45

MULTIVARIATE NETWORK META-ANALYSIS OF SURVIVAL FUNCTION PARAMETERS

Cope S1, Chan K1, Jansen JP2
1Precision Health Economics, Vancouver, BC, Canada, 2Precision Health Economics, Los Angeles, CA, USA

RM3

14:45 - 15:00

METHODS FOR EXTRACTING TREATMENT PATTERNS FOR RENAL CELL CARCINOMA (RCC) FROM SOCIAL MEDIA (SM) FORUMS USING NATURAL LANGUAGE PROCESSING (NLP) AND MACHINE LEARNING (ML)

Merinopoulou E1, Ramagopalan S2, Malcolm B2, Cox A1
1Evidera, London, UK, 2Bristol-Myers Squibb, Uxbridge, UK

RM4

15:00 - 15:15

NON-PROPORTIONAL HAZARDS IN NETWORK META-ANALYSIS: EFFICIENT STRATEGIES FOR MODEL BUILDING AND ANALYSIS

Gsteiger S1, Windisch R1, Bryden P1, Wiksten A2
1F. Hoffmann-La Roche Ltd, Basel, Switzerland, 2StatFinn & EPID Research, Espoo, Finland
15:45 - 16:45
BREAKOUT SESSION

15:45 - 16:45
Room: Hall 1
P5: MEDICATION ADHERENCE STUDIES
Moderator: Maureen Rutten-van Mölken, PhD
Associate Professor, School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

AD1

15:45 - 16:00

EXPLORING FACTORS EXPLAINING TREATMENT ACCEPTANCE IN PATIENTS SUFFERING FROM A CHRONIC DISEASE

Wiederkehr S1, de Bock E2, Chekroun M3, Arnould B4
1Mapi, Patient Centered Sciences, Lyon, France, 2Mapi, Patient-Centered Outcomes, Lyon, France, 3Carenity, Paris, France, 4Mapi, Patient Centered Outcomes, Lyon, France

AD2

16:00 - 16:15

THE IMPACT OF PHARMACIST-LED MEDICATION THERAPY MANAGEMENT ON MEDICATION ADHERENCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A RANDOMIZED CONTROLLED STUDY

Erku DA, Belachew SA, Tegegn HG, Ayele AA
University of Gondar, Gondar, Ethiopia

AD3

16:15 - 16:30

FACTORS ASSOCIATED WITH AN ADHERENCE WITH ANTIEPILEPTIC DRUGS IN CHILDREN TREATED IN PEDIATRIC PRACTICES IN GERMANY

Kostev K1, Dombrowski S1, Jacob L2
1QuintilesIMS, Frankfurt am Main, Germany, 2University of Paris 5, Paris, France

AD4

16:30 - 16:45

PREDICTIVE ANALYSIS FOR IDENTIFYING PATIENT CHARACTERISTICS ASSOCIATED WITH PRIMARY MEDICATION NONADHERENCE FOR LIPID LOWERING THERAPIES

Hill JW1, Rane PB2, Hines DM1, Patel J2, Harrison DJ2, Wade RL1
1QuintilesIMS, Plymouth Meeting, PA, USA, 2Amgen Inc., Thousand Oaks, CA, USA

15:45 - 16:45
Room: Forth (Armadillo)
P6: MENTAL HEALTH STUDIES
Moderator: Rok Hren, PhD, MSc, IHP (HE)
Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

MH1

15:45 - 16:00

DISCRETE EVENT SIMULATION MODELLING OF LONG TERM COST-EFFECTIVENESS OF INTERNET-BASED BLENDED COGNITIVE BEHAVIOURAL THERAPY FOR MAJOR DEPRESSIVE DISORDER: EXTRAPOLATION OF THE E-COMPARED RANDOMISED CONTROLLED TRIAL.

O'Connell MM1, Kolovos S2, Bosmans JE2, Forbes JF1, E-COMPARED Consortium .3
1University of Limerick, Limerick, Ireland, 2Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 3E-COMPARED Consortium, Europe, Ireland

MH2

16:00 - 16:15

ADHERENCE PATTERNS AMONG PATIENTS USING ORAL ATYPICAL ANTIPSYCHOTICS AND OTHER MEDICATIONS

Shafrin J1, Lakdawalla DN2, MacEwan JP1, Silverstein AR1, Hatch A3, Forma F4
1Precision Health Economics, Los Angeles, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3ODH, Inc., Princeton, NJ, USA, 4Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

MH3

16:15 - 16:30

MODEL STRUCTURE OF PATIENT-LEVEL MODELS FOR SCHIZOPHRENIA: A SYSTEMATIC LITERATURE REVIEW

Zhou J1, Millier A2, Dorey J2, Aballéa S2, Toumi M1
1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France

MH4

16:30 - 16:45

FAMILY CAREGIVING IN DEMENTIA AND ITS IMPACT ON QUALITY OF LIFE AND ECONOMIC BURDEN IN JAPAN – WEB-BASED SURVEY

Igarashi A1, Fukuda A1, Teng L1, Ma F2, Dorey J3, Onishi Y4
1University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan, 2Creativ-Ceutical, Beijing, China, 3Creativ-Ceutical, Paris, France, 4Creativ-Ceutical K.K., Tokyo, Japan
17:00 - 18:00
BREAKOUT SESSION

17:00 - 18:00
Room: Hall 1
P7: CONCEPTUAL PAPERS
Moderator: Andrej Srakar, PhD
Research Associate, Institute for Economic Research (IER), Ljubljana, Assistant Professor, Faculty of Economics, University of Ljubljana, Ljubljana, Slovenia

CP1

17:00 - 17:15

INNOVATIVE PRICING AND REIMBURSEMENT SCHEMES – THE WHAT, WHY, WHICH, AND HOW

Macaulay R, Hettle R
PAREXEL International, London, UK

CP2

17:15 - 17:30

USING OUTCOME DATA TO INFORM HEALTHCARE PROFESSIONAL – PATIENT DISCUSSION: A DATABASE OF TREATMENT EFFECTS

Gilbert J
National Guideline Centre, London, UK

CP3

17:30 - 17:45

THE FUTURE OF PRECISION MEDICINE: WHAT DOES IT MEAN FOR NICE?

Rejon-Parrilla JC1, Lovett RE2, Chalkidou A3, Love-Koh J4, Wood H4, Ennis K4, Peel A4, Taylor M4
1National Institute for Health and Care Excellence (NICE), Manchester, UK, 2National Institute for Health and Care Excellence (NICE), London, UK, 3King's Technology Evaluation Centre (KiTEC), King's College London, London, UK, 4York Health Economics Consortium, University of York, York, UK

CP4

17:45 - 18:00

CHALLENGES IN OPTIMISING REAL WORLD EVIDENCE FOR ALZHEIMER’S DISEASE

Reed C1, de Reydet de Vulpillieres F2, Gallacher J3
1Eli Lilly and Company Ltd, Windlesham, UK, 2NOVARTIS PHARMA AG, Basel, Switzerland, 3Oxford University, Oxford, UK

17:00 - 18:00
Room: Forth (Armadillo)
P8: CARDIOVASCULAR STUDIES
Moderator: Olivia Wu, PhD, MSc
Professor of Health Technology Assessment, Director of HEHTA, Director of NIHR Complex Reviews Support Unit, Institute of Health and Wellbeing, University of Glasgow, Health Economics and Health Technology Assessment (HEHTA) , Glasgow, UK

CV1

17:00 - 17:15

INTERIM RESULTS OF A MULTI-COUNTRY SURVEY TO EVALUATE PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER CARDIOVASCULAR EVENTS IN EUROPE

Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Amarenco P3, Kotseva K4, Annemans L5
1QuintilesIMS, Zaventem, Belgium, 2Amgen (Europe) GmbH, Zug, Switzerland, 3Bichat Hospital-Claude Bernard, Paris, France, 4National Heart & Lung Institute, Imperial College London, London, UK, 5Ghent University - Brussels University, Ghent, Belgium

CV2

17:15 - 17:30

A FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF NOVEL BIOMARKER TESTING IN CARDIOVASCULAR DISEASE

Kohli-Lynch CN, Boyd K, Briggs A, Delles C
University of Glasgow, Glasgow, UK

CV3

17:30 - 17:45

CYP2C19 GUIDED ANTIPLATELET THERAPY: A COST-EFFECTIVENESS ANALYSIS OF 30-DAY AND ONE-YEAR OUTCOMES FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Dong OM1, Borse MS1, Polasek MJ2, Farley JF1, Stouffer GA1, Lee CR1
1University of North Carolina, Chapel Hill, NC, USA, 2QuintilesIMS, Durham, NC, USA

CV4

17:45 - 18:00

COST MODEL FOR A NEW ACOUSTIC DIAGNOSTIC AID TO RULE OUT CORONARY ARTERY DISEASE

Winther S1, Böttcher M2, Wahler S3, Bolin K4
1Aarhus University Hospital, Aarhus N, Denmark, 2Hjertemedicin Hjerteforskningsklinikken, Herning, Denmark, 3St. Bernward GmbH, Hamburg, Germany, 4University of Gothenburg, Gothenburg, Sweden
Tuesday, 7 November 2017
8:45 - 9:45
BREAKOUT SESSION

8:45 - 9:45
Room: Hall 1
P9: MEDICAL DEVICE & DIAGNOSTICS STUDIES
Moderator: Katarzyna Kolasa, PhD
Principal Senior Consultant Market Access, Straub Medical, Wangs, Switzerland

MD1

8:45 - 9:00

DO WE KNOW ENOUGH YET? A CUMULATIVE COST-EFFECTIVENESS ANALYSIS OF MECHANICAL THROMBECTOMY

Teljeur C1, Ryan M2, Glynn R3, Harrington P4
1Health Information and Quality Authority, Dublin, Ireland, 2Health Information and Quality Authority (HIQA), Dublin, Ireland, 3Health Service Executive, Dublin, Ireland, 4Health Information and Quality Authority, Dublin 7, Ireland

MD2

9:00 - 9:15

SOUTH WEST ICERS – THE EXPERIENCE OF NICE’S DIAGNOSTICS ASSESSMENT PROGRAMME

Nixon F, Walker T, Maloney J, Albrow R
National Institute for Health and Care Excellence, Manchester, UK

MD3

9:15 - 9:30

COST-EFFECTIVENESS OF DIAGNOSIS: FROM TESTS TO LONG-TERM OUTCOMES AND COSTS

Faria R1, Soares M2, Spackman E3, Ahmed H4, Brown L5, Kaplan RS5, Emberton M6, Sculpher M2
1University of York, Heslington, York, UK, 2University of York, York, UK, 3University of Calgary, Calgary, AB, Canada, 4Imperial College Healthcare NHS Trust, London, UK, 5MRC Clinical Trials Unit at UCL, London, UK, 6University College Hospitals NHS Foundation Trust, London, UK

MD4

9:30 - 9:45

EVALUATING MATCHING-ADJUSTED INDIRECT COMPARISON AND SIMULATED TREATMENT COMPARISON TECHNIQUES: IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF FOCUSSED ULTRASOUND THALAMOTOMY AND OTHER INTERVENTIONS FOR THE TREATMENT OF MEDICATION-REFRACTORY ESSENTIAL TREMOR

Langford BE1, Ridley CJ1, Beale RC2, Marsh W1, Caseby SC1, Richard L3
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd, London, UK, 3InSightec Ltd, Tirat Carmel, Israel

8:45 - 9:45
Room: Gala (Armadillo)
P10: METHODS IN PATIENT PREFERENCE STUDIES
Moderator: Matthijs Versteegh, PhD
Business Director, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

PP1

8:45 - 9:00

MIMICKING REAL LIFE DECISION-MAKING IN HEALTH: ALLOWING RESPONDENTS TIME-TO-THINK IN A DISCRETE CHOICE EXPERIMENT

Veldwijk J1, Viberg Johansson J2, Donkers B1, de Bekker-Grob E1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Uppsala University, Uppsala, Sweden

PP2

9:00 - 9:15

CHOICE OF INSTRUMENT IMPACTS HEALTHCARE DECISIONS: EFFECT OF SOURCE OF UTILITY DERIVED FROM THE SAME PATIENT POPULATION ON COST-EFFECTIVENESS

Gunsoy NB1, Cockle SM2, Doyle S2, Asukai Y1
1GSK, Uxbridge, UK, 2GSK, Brentford, Middlesex, UK

PP3

9:15 - 9:30

THE COMPARATIVE PERFORMANCE OF THE CHU-9D AND ADQOL AMONGST CHILDREN AGED 5 YEARS OR MORE WITH ECZEMA: EVIDENCE FROM THE CLOTHES RANDOMISED CONTROLLED TRIAL

Sach TH1, McManus E1, Thomas K2, Montgomery A2, Harrison E2, Williams H2, on behalf of the CLOTHES trial team -2
1University of East Anglia, Norwich, UK, 2University of Nottingham, Nottingham, UK

PP4

9:30 - 9:45

DOES USING FACTOR ANALYSIS TO SELECT COVARIATES IN MAPPING ALGORITHMS IMPROVE PREDICTIVE ACCURACY? A CASE OF MAPPING THE CORE 23-ITEM WOMEN’S HEALTH QUESTIONNAIRE ONTO THE EQ-5D-5L AND SF-6D

Kaambwa B1, de Lacey S1, Smith C2, Ratcliffe J3
1Flinders University, Adelaide, Australia, 2Western Sydney University, Sydney, Australia, 3University of South Australia, Adelaide, Australia
14:00 - 15:00
BREAKOUT SESSION

14:00 - 15:00
Room: Hall 1
P11: COST STUDIES

CS1

14:00 - 14:15

OBSERVED VERSUS ESTIMATED ACQUISITION COSTS ASSOCIATED WITH MEDICINES RECOMMENDED BY THE ALL WALES MEDICINES STRATEGY GROUP

Keeping S, Deslandes PN, Haines K, Routledge PA
All Wales Therapeutics and Toxicology Centre, Llandough, UK

CS2

14:15 - 14:30

COSTS OF CHEMOTHERAPY-INDUCED ADVERSE EVENTS IN HEAD AND NECK CANCER IN FRANCE

Lafuma A1, Cotte F2, Le Tourneau C3, Emery C4, Gaudin A2, Torreton E1, Gourmelen J5, Ouared C2, Bonastre J6
1Cemka-Eval, Bourg La Reine, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 3Institut Curie, Paris, France, 4Cemka, Bourg La Reine, France, 5UMS 011 - Inserm - UVSQ, Villejuif, France, 6Gustave Roussy, Villejuif, France

CS3

14:30 - 14:45

COSTS OF ILLNESS PROGRESSION FOR DIFFERENT MULTIPLE SCLEROSIS PHENOTYPES: A POPULATION-BASED STUDY IN SWEDEN

Gyllensten H, Kavaliunas A, Hillert J, Alexanderson K, Tinghög P, Friberg E
Karolinska Institutet, Stockholm, Sweden

CS4

14:45 - 15:00

REAL LIFE COST OF TREATMENT AND FOLLOW-UP IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS TREATED AT THE ANTWERP UNIVERSITY HOSPITAL (UZA), BELGIUM

Van den Eede N1, De Paepe A1, Specenier P2, Strens D3
1University of Antwerp, Antwerpen, Belgium, 2Antwerp University Hospital, Edegem, Belgium, 3Realidad bvba, Grimbergen, Belgium

14:00 - 15:00
Room: Lomond Auditorium (Loch Suite)
P12: MODELING METHODS
Moderator: Talitha Feenstra, PhD
Assistant Professor, University Medical Center Groningen (UMCG), and National Institute for Public Health and the Environment (RIVM), Groningen, The Netherlands

MO1

14:00 - 14:15

CALIBRATION APPROACH IMPACT ON HEALTH AND COST-EFFECTIVENESS OUTCOMES IN A DECISION ANALYTIC FRAMEWORK

Moriña D, Díaz M
Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain

MO2

14:15 - 14:30

HOW IRELAND'S COLORECTAL SCREENING PROGRAMME COULD SAVE MORE LIVES, SAVE MONEY AND STAY WITHIN EXISTING COLONOSCOPY CAPACITY LIMITS: EVIDENCE FROM THE MISCAN MICROSIMULATION MODEL

McFerran E1, O'Mahony JF2
1QUEEN'S UNIVERSITY BELFAST, BELFAST, UK, 2Trinity College Dublin, Dublin, Ireland

MO3

14:30 - 14:45

MODELING COVARIATE-ADJUSTED SURVIVAL FOR ECONOMIC EVALUATIONS IN ONCOLOGY

Majer IM1, Castaigne J2, Palmer S3, DeCosta L4, Campioni M1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Oncology, Cambridge, UK, 3University of York, Heslington, York, UK, 4Amgen Ltd., Uxbridge, UK

MO4

14:45 - 15:00

DIFFERENT METHODS FOR MODELLING SEVERE HYPOGLYCAEMIC EVENTS: IMPLICATIONS FOR EFFECTIVENESS AND COST-EFFECTIVENESS ANALYSES

Keeney E1, Dawoud D2, Dias S1
1University of Bristol, Bristol, UK, 2National Guideline Centre, Royal College of Physicians, London, UK
15:30 - 16:30
BREAKOUT SESSION

15:30 - 16:30
Room: Hall 1
P13: METHODOLOGICAL STUDIES IN CANCER
Moderator: Ursula Rochau, MSc
Assistant Professor, UMIT - University for Health Sciences, Medical Informatics and Technology, Tirol, Austria

CN5

15:30 - 15:45

PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Dimopoulos M1, Sonneveld P2, Nahi H3, Kumar S4, Hashim M5, Kulakova M5, Duran M5, Heeg B5, Lam A6, Dearden L6
1National and Kapodistrian University of Athens, Athens, Greece, 2Erasmus MC, Rotterdam, The Netherlands, 3Karolinska Institute, Stockholm, Sweden, 4Mayo Clinic, Rochester, MN, USA, 5Ingress Health, Rotterdam, The Netherlands, 6Janssen Global Services, LLC, Raritan, NJ, USA

CN6

15:45 - 16:00

CAN BAYESIAN METHODOLOGY PREDICT LONG-TERM EFFECTIVENESS RATHER THAN EFFICACY? AN APPLICATION WITH OVERALL SURVIVAL IN TWO ONCOLOGY INDICATIONS

Soikkeli F1, Hashim M1, Mueller S2, Groth A2, Wilke T3, Heeg B1
1Ingress Health, Rotterdam, The Netherlands, 2Ingress-Health HWM GmbH, Wismar, Germany, 3INGRESS-Health HWM GmbH, Wismar, Germany

CN7

16:00 - 16:15

ESTIMATING LONG-TERM SURVIVAL IN THE FACE OF IMMATURE DATA: A CASE STUDY OF NIVOLUMAB IN SECOND LINE RENAL CELL CARCINOMA

Klijn SL1, Torkilseng EB2, Tyas D3, Sowdani A3, Malcolm B3, Mudd A1, Johannesen KM4
1Pharmerit International, Rotterdam, The Netherlands, 2Bristol-Myers Squibb, Lysaker, Norway, 3Bristol-Myers Squibb, Uxbridge, UK, 4Bristol-Myers Squibb AB, Stockholm, Sweden

CN8

16:15 - 16:30

LENGTH OF TRIAL PERIOD AND FIT OF STANDARD SURVIVAL EXTRAPOLATION DISTRIBUTIONS FOR IPILIMUMAB IN MELANOMA

Ouwens MJ, Dalevi D
Astrazeneca, Molndal, Sweden

15:30 - 16:30
Room: Forth (Armadillo)
P14: SYSTEMIC DISORDERS/CONDITIONS STUDIES
Moderator: Bertalan Nemeth, MSc
Senior Health Economist, Syreon Research Institute, President-elect of the ISPOR Hungary Chapter, Budapest, Hungary

SY1

15:30 - 15:45

PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISON BASED ON THE PRISM ACCESS DATABASE

Vollmer L1, de Paz B2, Droeschel D1, Walzer S1
1MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2PRIORITIS Market Access, Paris, France

SY2

15:30 - 15:45

WITHDRAWN

SY3

15:45 - 16:00

HOW WILL PAYERS MANAGE THE COST OF NEW, ADVANCED BIOLOGIC AND ONCOLOGIC AGENTS AS THERAPY AREAS BECOME CROWDED WITH DRUGS WITH SIMILAR MECHANISMS OF ACTION?

Paglia R, Del Carlo A, Schwartz J, Carter EA
Consulting at McCann Health, New York, NY, USA

SY4

16:00 - 16:15

DO EU5 COUNTRIES WITH FAVOURABLE HEALTHCARE EXPENDITURE AND REIMBURSEMENT INDICATORS HAVE BETTER PATIENT-REPORTED ACCESS TO TREATMENTS FOR RARE DISEASES?

Allen G1, Hall A1, Hanman K2, Le Fevre R1, Griffiths A1
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd, London, UK
16:45 - 17:45
BREAKOUT SESSION

16:45 - 17:45
Room: Hall 2
P15: HEALTH TECHNOLOGY ASSESSMENT STUDIES
Moderator: Hendrik Koffijberg, MSc, PhD
Associate Professor, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

HT5

16:45 - 17:00

“APPRAISING THE APPRAISERS”: DO NATIONAL HEALTH TECHNOLOGY ASSESSMENT AGENCIES (NICE, GBA/IQWIG) FOLLOW THEIR OFFICIAL EVALUATION CRITERIA?

Schaefer R1, Schwarz O2, Schlander M3
1German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany, 2University of Heilbronn, Wiesbaden, Germany, 3University of Heidelberg, Heidelberg, Germany

HT6

17:00 - 17:15

ASSESSMENT OF MEDICINES FOR VERY RARE CONDITIONS: REVIEW OF A NEW APPROACH WITHIN THE SCOTTISH MEDICINES CONSORTIUM

Jones J, Brown A, Lee A, MacDonald A
Healthcare Improvement Scotland, Glasgow, UK

HT7

17:15 - 17:30

WHAT DO THE SINGLE TECHNOLOGY APPRAISALS OF THE PAST TELL US ABOUT FAST-TRACKING THE MOST COST-EFFECTIVE NEW TECHNOLOGIES IN THE FUTURE?

Boland A1, Houten R1, Carroll C2, Kaltenthauer E2, Dickson R1
1University of Liverpool, Liverpool, UK, 2University of Sheffield, Sheffield, UK

HT8

17:30 - 17:45

THE USE OF PUBLISHED REAL-WORLD EVIDENCE IN HTA: AN ANALYSIS OF THE EVIDENCE BASE OF COMPANY SUBMISSIONS IN 2016 NICE APPRAISALS

Van Lier H, de Boeck M, Edwards V, Hanekamp E, Hartog TE, Richmond G, van den Broek R
Excerpta Medica, Amsterdam, The Netherlands

16:45 - 17:45
Room: Forth (Armadillo)
P16: INFECTIOUS DISEASE STUDIES
Moderator: JL (Hans) Severens, PhD
Professor of Evaluation in Health Care, Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, The Netherlands

IN1

16:45 - 17:00

ESTIMATING THE PUBLIC ECONOMIC IMPACT OF DIFFERENT HEPATITIS C HEALTHCARE POLICIES IN THE NETHERLANDS

Connolly M1, Kotsopoulos N2
1University of Groningen, Groningen, The Netherlands, 2Global Market Access Solutions, Saint-Prex, Switzerland

IN2

17:00 - 17:15

COST-EFFECTIVENESS AND MODELING APPROACHES OF DIRECT-ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC LITERATURE REVIEW

Szilberhorn L1, Ágh T2, Fasseeh AN1, Kaló Z1
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary

IN3

17:15 - 17:30

DIFFERENCES IN VACCINE PRICING BETWEEN HIGH-INCOME AND LOW-INCOME MARKETS

Fadeyi I, McLean T, Tavella F, Heron L
Adelphi Values Ltd, Bollington, UK

IN4

17:30 - 17:45

COST-EFFECTIVENESS OF ADDITIONAL VACCINATION OF BOYS AGAINST HPV IN GERMANY

Damm O1, Horn J2, Ultsch B3, Scholz S1, Mikolajczyk R2, Wiese-Posselt M3, Harder T3, Wichmann O3, Greiner W1
1School of Public Health, Bielefeld University, Bielefeld, Germany, 2Helmholtz Centre for Infection Research, Brunswick, Germany, 3Immunisation Unit, Robert Koch Institute, Berlin, Germany
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.